Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial -

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
Information type: Randomised controlled trials
Source: The Lancet Respiratory Medicine
Specialities: Cancers | Respiratory disorders
Summary
RCT (n=1202) noted improved survival with ABCP vs. BCP in patients with sensitising EGFR mutations (median not estimable vs 17.5months; HR 0·31;95% CI 0·11–0·83), baseline liver metastases (13.3 vs 9.4;0.52;0.33–0.82) and in intention-to-treat group (19.8 vs 14.9;0.76; 0.63–0.93)
UKMi comment
The IMpower150 trial compared atezolizumab plus bevacizumab plus carboplatin plus paclitaxel (ABCP) with the standard-of-care bevacizumab plus carboplatin plus paclitaxel (BCP). The primary analysis had reported significant improvements in progression-free and overall survival with ABCP in chemotherapy-naive patients with non-squamous non-small-cell lung cancer.
Related links: